Latest Partnerships News

Red Mountain Mining reports impressive gold assay results reaching 25.1 grams per tonne at its Fry Lake project in Ontario, reinforcing the prospect's potential and setting the stage for targeted drilling.

Imagion Biosystems has reached key milestones in its MagSense® HER2 breast cancer imaging program, including starting manufacturing for its Phase 2 trial and launching an AI imaging protocol collaboration with Wayne State University.

West Wits Mining has secured a $12.5 million USD loan facility from Nebari to fast-track development of its Qala Shallows Gold Project in South Africa, aiming for first gold production in early 2026.

Rewardle Holdings reported a modest revenue increase for FY25 but saw its loss more than double, driven by investments in AI-powered MedTech associate CloudHolter and expanded platform initiatives.

New Murchison Gold Limited has officially commenced production at its Crown Prince Gold Mine ahead of schedule, marking its transition from explorer to gold producer. The company aims to ramp up to a 40,000 tonne monthly ore run rate by October 2025.

Red Sky Energy has secured regulatory approval to build the KN2 well site at its Killanoola Oil Project, setting the stage for drilling a promising new target that could boost production and revenues.

Noronex Limited has confirmed deeper, higher-grade copper mineralisation at its Fiesta Project in Namibia through diamond drilling, setting the stage for a substantial 7,000m Reverse Circulation drilling campaign funded by South32.

4DMedical has secured multi-year agreements to deploy its advanced lung imaging technology across Brazil and Australia, supporting national lung cancer screening programs and enhancing lung health diagnostics.

Hazer Group and First Graphene have signed a non-binding MOU to explore innovative applications for Hazer’s proprietary graphite, aiming to capitalize on rising global demand amid supply constraints.

Pathkey.AI’s TrialKey platform has demonstrated a 73% alignment with actual biotech trial outcomes, showing an average hypothetical share price gain of 76%, underscoring AI’s growing role in clinical trial prediction and biotech investing.

Prophecy International flags higher churn and softer US sales for its Snare product, prompting a conservative FY2026 outlook and $3.2 million in annual cost savings.

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.